Weight-loss, Diabetes Drugs GLP-1: Govt Flags Serious Health Risks, Tightens Rules amid Rising Misuse and Safety Concerns

Moneylife Digital Team 01 April 2026

Life

The Indian government has issued a strong warning against the misuse of glucagon-like peptide-1 receptor agonists (GLP-1) drugs, widely used for treating type-2 diabetes and obesity, while stepping up regulatory action to curb their unauthorised sale across India.

A detailed statement released by press information bureau (PIB), says authorities have intensified surveillance following concerns over the growing availability of these drugs through retail pharmacies, online platforms, wholesalers, and wellness clinics without proper medical oversight.

GLP-1 drugs are a class of medications designed to regulate blood sugar and appetite. They work by stimulating insulin release and suppressing excess glucagon, thereby helping control blood glucose levels in patients suffering from type-2 diabetes. The drugs also slow gastric emptying, increasing the feeling of fullness and aiding weight loss, making them popular in obesity management.

However, the government has cautioned that unsupervised use of these drugs can lead to serious health complications. Side effects range from mild symptoms such as nausea and dizziness to severe conditions including pancreatitis and even medullary thyroid cancer.

To address the risks, drug controller general of India (DGCI) has stepped up enforcement measures. The regulator has made it clear that GLP-1 drugs can only be prescribed by qualified specialists, including endocrinologists, internal medicine experts and cardiologists.

As part of the crackdown, a nationwide inspection drive was recently conducted targeting the supply chain. According to the government, 49 entities, including online pharmacy warehouses, wholesalers, retailers and weight-loss clinics, were audited for violations such as unauthorised sale, improper prescriptions and misleading promotions. Notices have been issued to those found flouting norms.

Earlier, on 10 March 2026, the regulator issued a comprehensive advisory directing manufacturers to immediately stop misleading advertisements and promotions that encourage the use of GLP-1 drugs without a valid prescription.

Officials say surveillance and inspections will continue in the coming weeks, with strict penalties including licence cancellation, fines and legal action for non-compliance.

The government emphasised that, while GLP-1 drugs represent a significant medical advancement in managing diabetes and obesity, it must be used strictly under medical supervision due to their potential risks.

India is witnessing a growing burden of lifestyle diseases such as diabetes and obesity, driven by factors including poor diet, lack of physical activity and genetic predisposition. Health experts note that prevention remains critical, with emphasis on maintaining healthy body weight, regular exercise and balanced nutrition.

The statement also highlighted that obesity and diabetes are closely linked, with excess body weight—particularly abdominal fat—significantly increasing the risk of insulin resistance and related complications such as heart disease and stroke.

Authorities have urged patients to consult qualified medical practitioners before using GLP-1 drugs and to procure them only through authorised, prescription-based channels.

Comments

User

aiyerg

2 months ago

If you have a 'friendly' chemist, anything can be sourced, with or without Rx. They need to make the entire eco system tighter.

Life

Beyond Surgery: Why India Fails Spinal Cord Injury Patients after Hospital Discharge

Dr Ketna L. Mehta, 31 March 2026

India’s healthcare system has made significant advances in specialised and tertiary care. However, for individuals living with spinal cord injuries, medical intervention is only the beginning of a far more complex and often...